Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2026
Reporting Period: Event-specific report regarding a Pre-Submission Meeting with the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical and regulatory progress. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the outcome of a Pre-Submission Meeting with the FDA concerning the Helix Transendocardial Delivery Catheter System (Helix). Key developments include:
- Regulatory Pathways: The FDA identified two potential pathways for Helix marketing clearance.
- Safety and Performance: The FDA raised no concerns regarding Helix safety data, device performance, or compatibility with general classes of agents.
- Preferred Approval Route: The FDA indicated a preference for simultaneous approval of Helix alongside the CardiAMP cell therapy system for the treatment of heart failure.
- Alternative Pathway: The FDA suggested that a follow-on pre-submission incorporating agency advice could enable approval via the DeNovo pathway.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) detailing the positive reception of the Helix system by the FDA. The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: While the FDA raised no immediate concerns, the filing implies that future regulatory approval is contingent upon the outcomes of the suggested pathways (simultaneous approval or DeNovo pathway) and the execution of a follow-on pre-submission.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed technical data.
- Monitor future filings for the submission of the follow-on pre-submission mentioned by the FDA.
- Track the regulatory status of the CardiAMP cell therapy system, as Helix approval is linked to it in the FDA's preferred route.
- Review upcoming quarterly reports (10-Q) or annual reports (10-K) for financial impacts related to these regulatory milestones.